Browse Companies

Absci Corp employs a proprietary Integrated Drug Creation platform combining AI and automation to expedite biologic drug discovery, focusing on underexplored targets with high unmet need. Since commercial operations began in 2018, growth has been driven primarily by partnerships rather than product sales, leading to revenues plateauing below $6 million annually amid increasing R&D expenses. The lead candidate ABS-201 is advancing through Phase 1/2a trials for androgenetic alopecia with interim data expected in H2 2026, alongside plans for a Phase 2 trial in endometriosis. Absci faces significant operating losses exceeding $115 million in 2025, heavy cash burn, and absence of royalties from licensed products, underscoring challenges in translating platform innovation into sustainable profitability. Critical upcoming milestones center on clinical readouts and partner engagements that could validate the platform’s commercial potential.

Bright Mountain Media, Inc. has experienced a precipitous fall in revenues, from nearly $1.7 million in 2018 to just over $56,000 in 2023, accompanied by ongoing net losses and a deeply negative equity position. Despite some recovery in operating cash flow in 2025, the company faces severe liquidity constraints with $86.1 million of secured debt maturing mostly by year-end 2026, controlled by Centre Lane Partners. The highly concentrated customer base and seasonal advertising patterns add volatility to revenues. Intense competition, rapid AI-driven market changes, legal disputes including a $1.7 million judgment, and material weaknesses in internal controls further challenge its prospects. Management is pursuing strategic alternatives such as debt restructuring to improve financial stability, yet sizable refinancing needs remain critical milestones for investors to watch.

Strategic Storage Trust VI, Inc. reported continued operational performance tied closely to SmartStop’s technology-heavy property management platform in its May 2026 quarter. While the company benefits from geographic diversification and digital rental optimization capabilities, its financials reflect ongoing net losses, highlighting execution and market challenges. The firm's growth strategy hinges on leveraging under-market rents, expanding through acquisitions and developments, and consolidating self storage assets in fragmented U.S. and Canadian markets. Risks include dependence on affiliated Sponsor services and competitive industry dynamics. Future performance will hinge on rental rate improvements, occupancy trends, and capital deployment effectiveness.

Established in 2010, VOC Energy Trust holds a passive net profits interest entitling it to 80% of net proceeds from VOC Brazos-operated oil and gas assets. The Trust’s revenues and distributions have remained relatively stable due to its contractual structure, despite exposure to commodity price volatility and operator performance. Its net profits interest expires either in 2030 or upon reaching specified production thresholds, capping long-term growth. Capital expenditures are tightly controlled by contractual limits, influencing reserve additions and cash flow sustainability. Unitholders receive quarterly cash distributions predominantly driven by external production outcomes without operational control or leverage.

In its Q1 2026 results, Blaize Holdings reported revenue exceeding estimates driven by new contracts including a sizable $50 million agreement with NeoTensr, underscoring progress toward commercializing automotive-grade AI chips. The company’s business model balances proprietary AI chip sales and software platforms with lower-margin third-party hardware, reflecting a transition phase. Operating in a highly competitive AI semiconductor landscape, Blaize maintains strategic OEM and Tier-1 partnerships critical for entering the Advanced Driving Assistance Systems market with production slated for 2028 or later. Customer concentration, supply chain dependencies on foundries like Samsung, and long development cycles remain key constraints. Monitoring backlog developments and delivery milestones will be essential to gauge execution momentum.

Grayscale Sui Staking ETF (GSUI) commenced staking operations on February 18, 2026, alongside instituting a continuous share creation and redemption mechanism listed on NYSE Arca. These developments have materially increased market liquidity, enabling more efficient investor access and driving substantial net asset growth despite prevailing SUI price volatility. The Trust’s business model centers on providing passive, regulated exposure to the SUI token with embedded staking rewards, positioned competitively amidst growing demand for transparent, regulated digital asset vehicles. Notwithstanding, GSUI faces persistent challenges tied to digital asset volatility, regulatory uncertainties, and operational reliance on third parties for staking execution.

G-III Apparel reported a sharp decline in operating and net income for FY2025, with operating income down 63.2% and net income falling 65.2% year-over-year. Despite the contraction, the company maintains robust liquidity, evidenced by a current ratio of 2.69 and cash reserves exceeding $400 million as of January 31, 2026. Leadership continuity is being addressed through long-term RSU grants aimed at retaining key executives amid succession planning. However, business exits coupled with adverse economic conditions, including rising crude oil prices, weigh on future revenue growth and margin stability.

Fractyl Health, Inc. (GUTS) remains a clinical-stage company developing novel therapies for obesity and type 2 diabetes with its Revita device and Rejuva gene therapy candidates. While pivotal trial data for Revita are expected throughout 2026, the company faces significant net losses and operating cash flow deficits that raise substantial doubt about its ability to continue beyond early 2027 without additional capital. Cash reserves of $81.5 million at year-end 2025 provide some runway, but ongoing financing or partnerships will be critical to sustain operations amid regulatory complexities and competitive pressures.

Comstock Inc. has steadily expanded its metals recycling and renewable solar component recovery segments, supported by a $50 million capital raise completed in early 2026. Despite modest revenue generation, the company continues to face substantial net losses exacerbated by costly refinery development and site expansion efforts. Its balance sheet shows reasonable liquidity and manageable debt levels, but reliance on equity financing and director stock compensation introduces dilution risks. Investors should monitor the company’s ability to translate scale-up investments into improved cash flow and operational stability amid a complex regulatory landscape.

LENZ Therapeutics secured FDA approval for VIZZ, the first aceclidine-based eye drop for presbyopia, in mid-2025 and launched it commercially in the U.S. since August 2025. Despite this milestone, the company remains unprofitable with substantial operating losses and negative cash flow reflecting early commercialization investments. LENZ’s growth depends on market adoption of VIZZ within the large U.S. presbyopia population, scaling sales efforts, and protecting intellectual property amid competitive pressures. International licensing extends reach but increases reliance on partners. Monitoring sales traction, competitive landscape, and regulatory developments will be critical to assessing LENZ’s trajectory.

ECA Marcellus Trust I functions as a statutory trust owning royalty interests in natural gas producing and development wells concentrated in Greene County, Pennsylvania. Its cash flows derive from contractual arrangements with Greylock Production, which operates the wells, with distributions fluctuating alongside volatile natural gas prices and production volumes. The Trust faces constraints from its passive structure, exposure to third-party operator risks, and a scheduled termination in 2030 as its underlying reserves decline. Investors should track production trends, commodity price movements, and regulatory developments as key forward indicators.

Biomea Fusion, Inc., a clinical-stage biotech focused on metabolic disorders and oncology, continues its early-stage development with lead asset icovamenib in Phase II trials. Despite recent IND clearance for BMF-650 and strategic oncology portfolio planning, the company remains unprofitable with escalating net losses and negative cash flows. Its liquidity position stands adequate for near-term operations but raises concerns about sustainability without further financing. Regulatory complexities, patent litigation risks, and commercialization capabilities constitute substantial barriers ahead.

BioCardia, Inc. disclosed in its Q1 2026 10-Q that it remains non-compliant with Nasdaq's minimum stockholders' equity rule, registering only $895,000 against a $2.5 million threshold, triggering a submission deadline for a remediation plan by May 25, 2026. This financial strain coexists with ongoing advancements in its CardiAMP® cell therapy and the Helix™ delivery system, including FDA discussions on marketing pathways and clinical trial initiations. The company's business model hinges on clinical-stage partnerships and innovative biotherapeutic delivery platforms, which confer potential regulatory and competitive advantages but are contingent on regulatory approvals and further capital infusion. Moving forward, BioCardia’s near-term outlook depends heavily on Nasdaq’s acceptance of its compliance plan, progress in Phase III trials, and its ability to secure additional funding amid a low cash runway.

Commercial Bancgroup, Inc. closed 2025 with solid financial results highlighted by $37.2 million in net income and a 13% return on equity, supported by a $2.3 billion asset base primarily funded through stable core deposits. The October 2025 IPO raised nearly $30 million in net proceeds, which were largely deployed to retire holding company debt, enhancing capital flexibility for growth initiatives. The bank's growth strategy balances acquisitive expansion—exemplified by the 2024 Alliance Bank merger—with organic growth across Tennessee, Kentucky, and North Carolina markets where it holds top five deposit market shares in key counties. Investments in technology platforms like Jack Henry support operational scalability and customer experience. Key risks include regional economic concentration, competitive pressures from larger banks and fintechs, interest rate sensitivity, and regulatory compliance costs. Capital management remains conservative with a focus on maintaining well-capitalized status and a disciplined dividend policy.

Founded in 2018, Neurogene Inc. has concentrated its efforts on developing gene therapies using its patented EXACT platform, which employs microRNA genetic circuits to finely tune transgene expression—an innovation essential for dosage-sensitive neurological diseases like Rett syndrome. The company’s lead candidate NGN-401 is currently in Phase 3 registrational trials with encouraging interim clinical data, supported by an in-house cGMP manufacturing facility that enhances control over quality and timelines. Despite sustained operating losses driven by clinical advancement and R&D investment, Neurogene maintains a strong liquidity position but faces typical early-stage biotech risks including capital demands, regulatory uncertainties, and competitive pressures.

Titan America SA, a Belgium-incorporated firm majority-owned by Titan SA, commands a strong regional presence in the U.S. Southeast and Mid-Atlantic heavy building materials market. Its vertically integrated model spans raw materials to downstream concrete block production, supported by key regional assets such as the Pennsuco and Roanoke cement plants and multi-modal import terminals. The company exhibits steady revenue expansion driven by infrastructure demand and capacity investments, balanced against exposure to seasonal market swings and input cost volatility. Capital allocation emphasizes reinvestment for growth, with limited dividend payouts amid leverage management.

In its latest quarter ending March 31, 2026, Curis, Inc. continues its clinical-stage focus centered on emavusertib, an oral small molecule targeting IRAK4 and FLT3 in oncology. The company’s cash balance of $15 million supports operations for just under a year, highlighting pressing capital-raising needs given ongoing R&D expenses and milestone obligations tied to its Aurigene collaboration. Curis’ competitive position hinges on the exclusive licensing of promising immuno-oncology compounds but remains vulnerable to regulatory hurdles, reimbursement challenges, and the absence of commercial products following the recent sale of Erivedge royalty rights. Execution on late-stage trials and financial robustness will be critical to unlocking value and sustaining operations.

Sanara MedTech Inc. has recently achieved a significant turnaround in operating profitability following its strategic exit from the loss-making Tissue Health Plus (THP) program. By concentrating resources exclusively on its surgical portfolio—primarily soft tissue repair and bone fusion products—the company leveraged contract manufacturing efficiencies to improve margins, increasing operating income from a loss position to $7.3 million in 2025. Despite the operating income rebound and stronger cash flow, net losses deepened due to non-operating factors. The company faces risks from supplier concentration and competitive pressures as it advances pipeline innovations such as the OsStic BioAdhesive. Monitoring execution and adoption of new surgical technologies will be critical to sustaining growth.

Millicom International Cellular S.A. (Tigo) delivered a remarkable net income recovery in fiscal year 2025 with a 408% increase despite only modest revenue growth of 0.3%, underscoring operational improvements and strategic gains from joint ventures. Its extensive presence across emerging Latin American markets, supported by mobile and fixed broadband services totaling over 49 million mobile subscribers, anchors its competitive position. Key strategic moves include a joint acquisition of Telefonica’s Chilean operations and continued network expansion amid regulatory challenges. Capital deployment shows a notable rise in dividends alongside prudent debt management, signaling Millicom's evolving business model integrating fixed-mobile convergence and financial services.

ITHAX Acquisition Corp III remains a non-operating SPAC with $230 million raised in its December 2025 IPO and held securely in trust, reflected in a strong current ratio of 10.48 as of Q1 2026. The company is positioned financially to pursue a business combination but continues to face significant execution risk inherent to the SPAC model, including intense competition for deals and the risk of failing to close a merger within the mandated timeline. The development path going forward centers on target identification, deal negotiation, and securing shareholder approval amid evolving regulatory conditions.

Brookfield Oaktree Holdings, LLC operates as a holding company primarily invested in limited partner stakes of Oaktree Opportunities Funds XI and XII following a key 2024 restructuring. Revenue and income have shown volatility tied to fund commitments and performance, with a significant decline in revenue since 2018 but improving net income by 2025. The company’s cash flow profile reflects notable swings, highlighting timing mismatches inherent to investment vehicles limited to distribution inflows. Growth prospects rest on successful deployment and returns from these flagship opportunistic funds but face caps due to Oaktree’s deliberate asset management philosophy restraining fund size. Preferred unit distributions depend on underlying fund distributions without guaranteed cash availability, constrained further by operating agreement provisions limiting unitholder remedies. Capital allocation is characterized by a sizable equity base and recent positive operating cash flows, yet dividend history is dated, and capital returns remain uncertain. Regulatory scrutiny and litigation risks permeate the broader investment management ecosystem where Brookfield Oaktree operates. Going forward, market conditions, fund deployment pace, and regulatory developments warrant close monitoring.

Southern California Edison Company (SCE), a wholly owned Edison International subsidiary, functions primarily as a regulated electric utility in California. Its most recent detailed financial disclosures date back over a decade, with key business descriptions and risk factors omitted in recent SEC filings, reducing transparency. SCE’s growth is tied to regulatory approvals and capital-intensive infrastructure investment, while its financing strategy increasingly involves asset-backed securities through a specialized subsidiary. Historical financials show steady operating income and moderate net income growth through 2011, but free cash flow remains challenged due to large capital expenditures.

Chicago Rivet & Machine Co. reported Q1 2026 selling and administrative expenses down 15.6% year-over-year, reflecting ongoing efficiency efforts. However, revenues remain pressured by automotive industry softness, contributing to recurring operating losses and liquidity constraints, with the company relying on a $2.5 million revolving credit line. Strategic actions including asset sales and renewed sales efforts aim to stabilize operations amid continued macroeconomic uncertainty.

CreditRiskMonitor.com reported a modest 2% increase in operating revenues for Q1 2026 driven by increased subscription sales to new and existing customers along with strategic price hikes. Despite a 10% rise in data and product costs due to technology investments and infrastructure changes, the company maintains strong operational resilience through its proprietary bankruptcy risk models and diversified enterprise customer base. The SaaS model anchored by CreditRiskMonitor® and SupplyChainMonitor™ serves credit and supply chain risk professionals with unique predictive analytics, fostering high customer retention and potential growth via cross-selling. Liquidity remains strong with $5.7 million in cash and no debt, supporting ongoing investments amid competitive industry dynamics.

VenHub Global, established in 2023, operates two company-owned autonomous retail stores that integrate robotics and AI for a 24/7 employee-free shopping experience. Despite promising technology and a growing patent portfolio supporting its integrated retail platform, the company remains early-stage with minimal revenue and substantial operating losses. Its future growth hinges on transitioning from prototype to scalable commercial deployments amid intense competition, complex regulatory compliance, and capital constraints. VenHub’s financials reflect steep net losses exceeding $62 million at year-end 2025 on just $864K revenue, highlighting a precarious going concern status. Upcoming milestones include expanding store deployments and advancing AI personalization features, all while defending its brand amidst trademark disputes.

Circle Energy remains an exploration-stage company focused on consolidating leasehold interests in the Permian Basin, specifically in Andrews County, Texas. The latest quarterly filings reaffirm the company’s stable risk profile and ongoing efforts toward geological evaluation and capital formation, with no wells drilled yet but drilling obligations looming by mid-2028. Its competitive moat is modest, tethered mainly to its working interests and joint venture acreage expansion. Key near-term risks revolve around securing sufficient drilling capital and meeting contractual drilling deadlines to preserve lease rights.

Perma-Fix Environmental Services Inc (PESI) operates in a highly regulated niche of nuclear and mixed waste management, serving predominantly U.S. government clients alongside growing international business. While 2025 revenue plunged dramatically due to the divestiture of legacy operations, improvements in treatment segment backlog and international contracts provide potential growth avenues. Significant risks remain from regulatory dependencies, government funding delays, and sustained operating losses with negative cash flow trends. The company is advancing its proprietary PFAS destruction technology as a strategic growth initiative within its broader remediation portfolio.

Leatt Corp returned to profitability in FY2025 after prior years of operating losses, supported by a 40.6% revenue surge and a 234.6% rebound in operating income. This recovery is anchored by its exclusive rights to the patented Leatt-Brace® neck protection system, which benefits from extensive international safety certifications. The company operates a diversified global supply chain with manufacturing primarily in China alongside growing capacity in Southeast Asia, enabling responsive expansion and risk mitigation. Despite a decline in operating cash flow in 2025 compared with 2024, the firm maintains a strong liquidity position and prudent capital expenditure approach. Looking forward, Leatt faces opportunities for growth via direct-to-consumer digital channels and OEM partnerships but must navigate ongoing geopolitical supply risks and patent litigation.

COMPASS Pathways plc reported significant advancements in its late-stage clinical development of COMP360, a proprietary psilocybin formulation targeting treatment-resistant depression (TRD). The first Phase 3 pivotal trial met primary endpoints with robust statistical significance, reinforcing its potential as a novel mental health therapy. Despite not generating revenue yet, COMPASS maintains strong financial health with over $466 million in cash and manageable debt, supporting ongoing development and commercialization preparations. The company faces evolving regulatory hurdles and operational risks related to third-party manufacturing and healthcare compliance but benefits from intellectual property protections and an emerging network for therapy administration.

Core & Main, Inc. commands a significant position in the fragmented $44 billion waterworks distribution market with over 370 branches servicing municipal, non-residential, and residential end markets. The company’s fiscal 2025 results show stable operating income of $722 million despite a slight downturn, while net income rose 20% to $441 million supported by improved cash flows. Growth outlook hinges on continued municipal infrastructure spending and the company’s extensive product portfolio and distribution network, but challenges include cyclical construction markets, supply chain complexities, and substantial indebtedness that imposes operational constraints. Capital allocation includes an expanded $1 billion share repurchase authorization, though dividends remain discretionary and debt covenants limit financial flexibility.

Cadeler A/S has demonstrated strong historical growth anchored by its specialized fleet of ten jack-up wind installation vessels, complemented by recent crane upgrades and two new A-Class vessels under construction. The company reported sharp profit and adjusted EBITDA improvements in 2025, supported by increasing vessel utilization and expanded fleet capabilities. While its capital-intensive expansion has raised leverage and finance costs, Cadeler maintains covenant compliance through refinancing and access to green financing facilities. Looking ahead, vessel deliveries scheduled through early 2026 and a robust order book underpin growth prospects amid global offshore wind market tailwinds. Currency exposure and regulatory dynamics pose notable risks that management actively mitigates.

Energy Focus, Inc. reported a 26.7% revenue decline to $3.56 million in 2025 amid sustained operating losses of over $1 million as it pivots from its core military maritime LED lighting market toward emerging segments such as energy storage systems (ESS), GaN power supplies, and AI data center UPS solutions. The firm's revenue concentration remains high with the U.S. Navy distributor accounting for 21% of sales in 2025 despite a 43% drop in military maritime market sales overall. While the company has pursued multiple private placements during 2025 to bolster liquidity, ongoing cash flow deficits raise concerns over continued operational funding. Strategic efforts include geographic expansion into Asia, product innovation focused on health-conscious lighting and high-efficiency power electronics, and strengthening defense-related partnerships, though stiff competition and tariff risks persist.

FiscalNote Holdings, Inc. specializes in AI-driven legislative tracking and policy intelligence through its flagship PolicyNote platform, generating the majority of revenue from subscription services. The company’s recent focus has shifted towards streamlining operations by divesting non-core assets and expanding into adjacent markets like political prediction and APIs. Despite efforts to rationalize costs, FiscalNote faces persistent operating losses and negative cash flows, with liquidity concerns magnified by covenant breaches on its senior term loan. Its competitive moat relies on integrating policy data with AI and grassroots tools, but customer retention issues and macroeconomic factors constrain growth prospects.

Smithfield Foods, having completed its IPO in early 2025, exemplifies steady top-line growth anchored in an integrated value chain spanning hog production, fresh pork processing, and packaged meats. The company’s focus on margin-accretive product innovation and manufacturing automation underpins improved operating income despite raw material cost pressures. Strategic capital allocation via refinancing and dividend growth supports operational agility and shareholder returns while international exports face tariff challenges. Key risks include commodity volatility, regulatory scrutiny, and cybersecurity oversight.

In 2025, Suzano S.A., a leading Brazilian pulp and paper company, reversed a significant net loss from the prior year to report a robust net income of R$13.44 billion, driven by volume gains and favorable USD/BRL exchange effects despite lower pulp prices. The company’s vertically integrated model, innovation centers, and diversified product portfolio underpin its competitive moat. Liquidity remains healthy with cash and marketable securities totaling over R$25 billion and undrawn credit lines extended through 2031. Key risks include commodity price swings and currency volatility. Suzano’s capital allocation includes dividends aligned with cash flow generation and a recent share buyback program aiming to optimize shareholder returns.

Achieve Life Sciences continues to solidify its development and upcoming commercialization of cytisinicline, a smoking cessation drug candidate. The completion of the pivotal ORCA-OL trial in late 2025 reduced R&D expenses but launched a surge in administrative costs linked to commercial readiness. A significant leadership change occurred with Dr. Andrew Goldberg assuming CEO duties in April 2026, signaling an intensified focus on market entry execution. While the company maintains a robust liquidity position with nearly $21 million in cash and a strong current ratio, financial sustainability remains dependent on timely regulatory approval and further financing. The smoking cessation therapy market is competitive and mature, posing both hurdles and opportunities for cytisinicline’s uptake.